Barinthus Biotherapeutics plc (BRNS)
NASDAQ: BRNS · Real-Time Price · USD
0.662173
-0.0362 (-5.19%)
At close: Jun 18, 2026, 4:00 PM EDT
0.6900
+0.0278 (4.20%)
After-hours: Jun 18, 2026, 4:53 PM EDT
Barinthus Biotherapeutics Earnings Call Transcripts
Fiscal Year 2025
-
The presentation highlighted a focus on the SNAP-TI nanoparticle platform for autoimmune diseases, with lead candidate VTP-1000 in phase I trials for celiac disease and data expected late 2024. Viral-based programs showed promising results in hepatitis B and are now open for partnering.
Fiscal Year 2024
-
The conference highlighted a strategic pivot to immune system therapeutics, with advanced HBV and celiac programs leveraging two proprietary platforms. Promising interim HBV data and a robust financial position support ongoing trials, with key data readouts expected in 2025.